Clinuvel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Clinuvel Pharmaceuticals has a total shareholder equity of A$178.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$211.7M and A$33.0M respectively. Clinuvel Pharmaceuticals's EBIT is A$43.8M making its interest coverage ratio -19.1. It has cash and short-term investments of A$174.4M.
Key information
0%
Debt to equity ratio
AU$0
Debt
Interest coverage ratio | -19.1x |
Cash | AU$174.45m |
Equity | AU$178.65m |
Total liabilities | AU$33.03m |
Total assets | AU$211.68m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CLVL.Y's short term assets (A$201.5M) exceed its short term liabilities (A$29.4M).
Long Term Liabilities: CLVL.Y's short term assets (A$201.5M) exceed its long term liabilities (A$3.6M).
Debt to Equity History and Analysis
Debt Level: CLVL.Y is debt free.
Reducing Debt: CLVL.Y has not had any debt for past 5 years.
Debt Coverage: CLVL.Y has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CLVL.Y has no debt, therefore coverage of interest payments is not a concern.